Cited by 2,561Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M·2013·The Lancet

DOI 10.1016/s0140-6736(13)60733-3

Open this paper in CoChat — free account

Abstract

Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)60733-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citation
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521

Show all 61 references

Research works printed but not linked: 1

Leucht, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368 · DOI

Sorted by citations

Items 201–300 of 1,006

Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis
Yaegashi, H., Kirino, S., Remington, G. J., Misawa, F., & Takeuchi, H. (2020) · CNS Drugs · doi:10.1007/s40263-020-00713-9 · Cited by 96
Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis
Su, X., Xie, X., Liu, L., Lv, J., Song, F., Perkovic, V., & Zhang, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.07.033 · Cited by 95
Applications of blood-based protein biomarker strategies in the study of psychiatric disorders
Chan, M. K., Gottschalk, M. G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.08.002 · Cited by 98
A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach
Citrome, L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0105-7 · Cited by 94
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone
Schoretsanitis, G., Spina, E., Hiemke, C., & de León, J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1345623 · Cited by 94
Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality
Schmitt, A., Maurus, I., Rossner, M. J., Röh, A., Lembeck, M., von Wilmsdorff, M., Takahashi, S., Rauchmann, B., Keeser, D., Hasan, A., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00690 · Cited by 111
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Lobo, M. C., Whitehurst, T., Kaar, S. J., & Howes, O. D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.032 · Cited by 97
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review
Veerman, S. R. T., Schulte, P. F. J., & de Haan, L. (2017) · Drugs · doi:10.1007/s40265-017-0789-y · Cited by 105
Antipsychotic use and risk of life‐threatening medical events: umbrella review of observational studies
Papola, D., Ostuzzi, G., Gastaldon, C., Morgano, G. P., Dragioti, E., Carvalho, A. F., Fusar‐Poli, P., Correll, C. U., Solmi, M., & Barbui, C. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13066 · Cited by 95
Self-citation
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis
Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., Song, Y., Liu, X., Wang, M., Zhang, L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1539-0 · Cited by 95
Quinoline- and Isoquinoline-Sulfonamide Analogs of Aripiprazole: Novel Antipsychotic Agents?
Zajdel, P., Partyka, A., Marciniec, K., Bojarski, A. J., Pawłowski, M., & Wesołowska, A. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.158 · Cited by 89
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Parellada, E., & Bioque, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0350-7 · Cited by 90
Neuroleptic malignant syndrome: an easily overlooked neurologic emergency
Oruch, R., Pryme, I., Engelsen, B., & Lund, A. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s118438 · Cited by 75
Repurposing psychiatric drugs as anti-cancer agents
Huang, J., Zhao, D., Liu, Z., & Liu, F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.058 · Cited by 89
Schizophrenia: One Name, Many Different Manifestations
Faden, J., & Citrome, L. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.05.005 · Cited by 89
Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms
Vasconcelos, G. S., Ximenes, N. C., de Sousa, C. N. S., Oliveira, T. D. Q., Lima, L. L. L., de Lucena, D. F., Gama, C. S., Macêdo, D. S., & Vasconcelos, S. M. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.017 · Cited by 89
Efficacy, Acceptability and Tolerability of Antipsychotics in Patients with Schizophrenia and Comorbid Substance Use. A Systematic Review and Meta-Analysis
Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86
Self-citation
Is It Possible to Predict the Future in First-Episode Psychosis?
Suvisaari, J., Mantere, O., Keinänen, J., Mäntylä, T. J. S., Rikandi, E., Lindgren, M., Kieseppä, T., & Raij, T. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00580 · Cited by 96
The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis
McCutcheon, R. A., Pillinger, T., Mizuno, Y., Montgomery, A., Pandian, H., Vano, L. J., Marques, T. R., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0502-5 · Cited by 89
Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
Caruso, G., Grasso, M., Fidilio, A., Tascedda, F., Drago, F., & Caraci, F. (2020) · Pharmaceuticals · doi:10.3390/ph13120457 · Cited by 91
The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study
Perry, B. I., Burgess, S., Jones, H. J., Zammit, S., Upthegrove, R., Mason, A. M., Day, F. R., Langenberg, C., Wareham, N. J., Jones, P. B., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003455 · Cited by 91
Eating Disorders in Schizophrenia: Implications for Research and Management
Kouidrat, Y., Amad, A., Lalau, J., & Loas, G. (2014) · Schizophrenia Research and Treatment · doi:10.1155/2014/791573 · Cited by 87
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Solmi, M., Pigato, G., Kane, J. M., & Correll, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s133205 · Cited by 88
Relationships between psychiatric symptoms, functioning and personal recovery in psychosis
Best, M. W., Law, H., Pyle, M., & Morrison, A. P. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.026 · Cited by 91
The activities of drug inactive ingredients on biological targets
Pottel, J., Armstrong, D., Zou, L., Fekete, A., Huang, X., Torosyan, H., Bednarczyk, D., Whitebread, S., Bhhatarai, B., Liang, G., et al. (2020) · Science · doi:10.1126/science.aaz9906 · Cited by 91
Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis
Martino, D., Karnik, V., Osland, S., Barnes, T. R. E., & Pringsheim, T. M. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718777392 · Cited by 91
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial
Flint, A. J., Meyers, B. S., Rothschild, A. J., Whyte, E. M., Alexopoulos, G. S., Rudorfer, M. V., Marino, P., Banerjee, S., Pollari, C. D., Wu, Y., et al. (2019) · JAMA · doi:10.1001/jama.2019.10517 · Cited by 85
Brexpiprazole: so far so good
Das, S., Barnwal, P., Aruldhas, B. W., Mondal, S., & Saha, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315614739 · Cited by 84
The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
Nasrallah, H. A., Earley, W. R., Cutler, A. J., Wang, Y., Lu, K., Laszlovszky, I., Németh, G., & Durgam, S. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1459-z · Cited by 87
Antipsychotic drug use and pneumonia: Systematic review and meta-analysis
Dzahini, O., Singh, N., Taylor, D. M., & Haddad, P. M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118795333 · Cited by 82
Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
Cerveri, G., Gesi, C., & Mencacci, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s201726 · Cited by 84
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
Gómez‐Revuelta, M., Pelayo‐Terán, J. M., Juncal‐Ruíz, M., Vázquez-Bourgón, J., Suárez‐Pinilla, P., Romero-Jiménez, R., Setién‐Suero, E., Ayesa‐Arriola, R., & Crespo‐Facorro, B. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa004 · Cited by 94
Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends
Sabé, M., Chen, C., Perez, N., Solmi, M., Mucci, A., Galderisi, S., Strauss, G. P., & Kaiser, S. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104979 · Cited by 87
Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials
Xiang, Y.-Q., Zheng, W., Wang, S.-B., Yang, X.-H., Cai, D.-B., Ng, C. H., Ungvari, G. S., Kelly, D. L., Xu, W.-Y., & Xiang, Y.-T. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.012 · Cited by 83
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
Citrome, L., McEvoy, J. P., Todtenkopf, M. S., McDonnell, D., & Weiden, P. J. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s209284 · Cited by 87
Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study
Morrison, A. P., Law, H., Carter, L., Sellers, R., Emsley, R., Pyle, M., French, P., Shiers, D., Yung, A. R., Murphy, E., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30096-8 · Cited by 88
Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials
Schneider‐Thoma, J., Efthimiou, O., Huhn, M., Krause, M., Reichelt, L., Röder, H., Davis, J. M., Salanti, G., & Leucht, S. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30177-9 · Cited by 83
Self-citation
Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
Khouri, C., Petit, C., Tod, M. M., Lepelley, M., Revol, B., Roustit, M., & Cracowski, J. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.01.015 · Cited by 83
The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service
Breitborde, N. J. K., Bell, E. K., Dawley, D., Woolverton, C. B., Ceaser, A. E., Waters, A. C., Dawson, S. C., Bismark, A. W., Polsinelli, A. J., Bartolomeo, L. A., et al. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0650-3 · Cited by 82
National Lipid Association Annual Summary of Clinical Lipidology 2015
Bays, H. E., Jones, P. H., Brown, W. V., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.002 · Cited by 82
Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature
Greenberg, W. M., & Citrome, L. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0465-5 · Cited by 84
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors
Niemann, N., & Jankovic, J. J. (2018) · Drugs · doi:10.1007/s40265-018-0874-x · Cited by 80
Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study
Hasan, A., Wolff-Menzler, C., Pfeiffer, S., Falkai, P., Weidinger, E., Jobst, A., Hoell, I., Malchow, B., Yeganeh-Doost, P., Strube, W., et al. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0618-9 · Cited by 80
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Citrome, L. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000665 · Cited by 92
Longitudinal Trends in Childhood Insulin Levels and Body Mass Index and Associations With Risks of Psychosis and Depression in Young Adults
Perry, B. I., Štochl, J., Upthegrove, R., Zammit, S., Wareham, N. J., Langenberg, C., Winpenny, E. M., Dunger, D. B., Jones, P. B., & Khandaker, G. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.4180 · Cited by 85
Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
Amato, D., Vernon, A. C., & Papaleo, F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 81
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 81
Thinking Well: A randomised controlled feasibility study of a new CBT therapy targeting reasoning biases in people with distressing persecutory delusional beliefs
Waller, H., Emsley, R., Freeman, D., Bebbington, P., Dunn, G., Fowler, D., Hardy, A., Kuipers, E., & Garety, P. (2015) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2015.02.007 · Cited by 77
Psychopharmacology in Cancer
Thekdi, S. M., Trinidad, A. C., & Roth, A. J. L. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0529-x · Cited by 77
A safety evaluation of aripiprazole in the treatment of schizophrenia
Preda, A., & Shapiro, B. B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1832990 · Cited by 77
Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis
Huhn, M., Nikolakopoulou, A., Schneider‐Thoma, J., Krause, M., Samara, M. T., Peter, N. L., Arndt, T. J., Bäckers, L., Rothe, P., Cipriani, A., et al. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18306 · Cited by 85
Self-citation
American psychiatry in the new millennium: a critical appraisal
Scull, A. T. (2021) · Psychological Medicine · doi:10.1017/s0033291721001975 · Cited by 94
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 81
Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials
Jensen, K. G., Juul, K., Fink‐Jensen, A., Correll, C. U., & Pagsberg, A. K. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.10.002 · Cited by 78
Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
Jauhar, S., & Young, A. H. (2019) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0145-0 · Cited by 77
Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review
Takeuchi, H., Suzuki, T., Remington, G. J., & Uchida, H. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000503 · Cited by 76
Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment
Nielsen, M. Ø., Rostrup, E., Wulff, S., Glenthoj, B. Y., & Ebdrup, B. H. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2582 · Cited by 76
The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study
Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Natesan, S., Turkheimer, F., Stone, J., Egerton, A., McGuire, P., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.07.003 · Cited by 75
Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties
Chen, Z., Fan, L., Wang, H., Yu, J., Lu, D., Qi, J., Nie, F., Luo, Z., Liu, Z., Cheng, J., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00971-w · Cited by 74
Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism
Citrome, L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.908185 · Cited by 75
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose–response study
Chen, J.-X., Su, Y., Bian, Q., Wei, L.-H., Zhang, R., Liu, Y.-H., Correll, C. U., Soares, J. C., Yang, F.-D., Wang, S.-L., et al. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.04.011 · Cited by 75
Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics.
de Leon, J. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.033 · Cited by 75
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 76
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000123 · Cited by 74
The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
Tandon, R., Lenderking, W. R., Weiss, C., Shalhoub, H., Barbosa, C. D., Chen, J., Greene, M., Meehan, S. R., Bouérat, L., Arango, C., et al. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00292-5 · Cited by 73
Chronic Stress, Exercise and Cardiovascular Disease: Placing the Benefits and Risks of Physical Activity into Perspective
Franklin, B. A., Rusia, A., Haskin-Popp, C., & Tawney, A. M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189922 · Cited by 89
Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice
Park, S. M., Chen, M., Schmerberg, C. M., Dulman, R. S., Rodriguiz, R. M., Caron, M. G., Jin, J. J., & Wetsel, W. C. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.196 · Cited by 74
Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis
Brunoni, A. R., Shiozawa, P., Truong, D. Q., Javitt, D. C., Elkis, H., Fregni, F., & Bikson, M. (2014) · Expert Review of Medical Devices · doi:10.1586/17434440.2014.911082 · Cited by 75
Comparative Efficacy and Tolerability of Three Treatments in Old People with Osteoporotic Vertebral Compression Fracture: A Network Meta-Analysis and Systematic Review
Chen, L., Li, Y., Ning, G., Li, Y., Wu, Q., Guo, J., Shi, H., Wang, X., Zhou, Y., & Feng, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123153 · Cited by 73
High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of China
Zhang, H., Mi, W., Li, L., Shi, Y., & Xiao, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s72367 · Cited by 72
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Davis, R. E., & Correll, C. U. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1174577 · Cited by 72
Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016
Højlund, M., Pottegård, A., Johnsen, E., Kroken, R. A., Reutfors, J., Munk‐Jørgensen, P., & Correll, C. U. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13945 · Cited by 69
Neuropsychiatric symptoms in dementia
Radue, R. M., Walaszek, A., & Asthana, S. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00024-8 · Cited by 70
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 74
Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses
Cella, M., Roberts, S., Pillny, M., Riehle, M., O'Donoghue, B. N., Lyne, J., Tomlin, P., Valmaggia, L., & Preti, A. (2023) · The British Journal of Psychiatry · doi:10.1192/bjp.2023.21 · Cited by 75
Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.
Potvin, S., Zhornitsky, S., & Stip, É. (2015) · Europe PMC (PubMed Central) · Cited by 73
Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: A meta-analysis
Bartoli, F., Lax, A., Crocamo, C., Clerici, M., & Carrà, G. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.03.012 · Cited by 72
Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews
Ribeiro, E. L. A., Lima, T. D. M., Vieira, M. E. B., Storpirtis, S., & Aguiar, P. M. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2498-1 · Cited by 71
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 74
Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real‐world observational study
Vanasse, A., Blais, L., Courteau, J., Cohen, A. A., Roberge, P., Larouche, A., Grignon, S., Fleury, M., LESAGE, A. D., Demers, M., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12621 · Cited by 72
The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach
Polcwiartek, C., Sneider, B., Graff, C., Taylor, D. M., Meyer, J. M., Kanters, J. K., & Nielsen, J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4024-9 · Cited by 69
Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment
Reynolds, G. P., & McGowan, O. O. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117722987 · Cited by 67
Clozapine in bipolar disorder: A systematic review and meta-analysis
Delgado, A., Velosa, J., Zhang, J., Dursun, S. M., Kapczinski, F. P., & Cardoso, T. D. A. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.02.026 · Cited by 72
Pharmacological treatment of negative symptoms in schizophrenia
Möller, H., & Czobor, P. (2015) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-015-0596-y · Cited by 69
Quetiapine safety in older adults: a systematic literature review
El‐Saifi, N., Moyle, W., Jones, C., & Tuffaha, H. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12357 · Cited by 71
Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy
Ostuzzi, G., Mazzi, M. A., Terlizzi, S., Bertolini, F., Aguglia, A., Bartoli, F., Bortolaso, P., Callegari, C., Caroleo, M., Carrà, G., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201371 · Cited by 68
Self-citation
Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval
Barbui, C., Bighelli, I., Carrà, G., Castellazzi, M., Lucii, C., Martinotti, G., Nosè, M., Ostuzzi, G., & STAR NETWORK INVESTIGATORS (2016) · PLoS ONE · doi:10.1371/journal.pone.0148212 · Cited by 68
Self-citation
Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort
Fond, G. B., Godin, O., Boyer, L., Berna, F. S., Andrianarisoa, M., Coulon, N., Brunel, L., Bulzacka, E., Aouizerate, B., Capdevielle, D., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0908-0 · Cited by 70
Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review
Thien, K., & O'Donoghue, B. N. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12683 · Cited by 67
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
Batalla, A., Bos, J., Postma, A., & Bossong, M. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618184 · Cited by 75
Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics
Rabkin, S. W. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000502 · Cited by 66
Ventricular repolarization measures for arrhythmic risk stratification
Monitillo, F. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i1.57 · Cited by 66
Understanding the Effects of Antipsychotics on Appetite Control
Mukherjee, S., Skrede, S., Milbank, E., Andriantsitohaina, R., López, M., & Fernø, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.815456 · Cited by 73
In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy
Loryan, I., Melander, E., Svensson, M., Payan, M., König, F., Jansson, B., & Hammarlund‐Udenaes, M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.229 · Cited by 66
Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia
Kane, J. M., Skuban, A., Hobart, M., Ouyang, J., Weiller, E., Weiss, C., & Correll, C. U. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.013 · Cited by 67
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12982 · Cited by 66
Classics in Chemical Neuroscience: Xanomeline
Bender, A. M., Jones, C. K., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00001 · Cited by 65
Prediction of response to drug therapy in psychiatric disorders
Stern, S., Linker, S. B., Vadodaria, K. C., Marchetto, M. C., & Gage, F. H. (2018) · Open Biology · doi:10.1098/rsob.180031 · Cited by 65
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
Zhu, M., Liu, Z.-J., Hu, Q.-Y., Yang, J., Jin, Y., Zhu, N., Huang, Y., Shi, D.-H., Liu, M.-J., Tan, H.-Y., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00420-0 · Cited by 65

Authors: Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M.
Affiliations: TUM Klinikum (DE)
University of Verona (IT)
University of Ioannina (GR)
Ludwig-Maximilians-Universität München (DE)
Warneford Hospital (GB)
University of Illinois Chicago (US)
Corresponding author: Leucht, Stefan
ORCID: Leucht, Stefan
Cipriani, Andrea
Spineli, Loukia
Mavridis, Dimitris
Samara, Myrto
Barbui, Corrado
Engel, Rolf R
Geddes, John R
Salanti, Georgia
Davis, John M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2013-09
Volume: 382
Issue: 9896
Pages: 951-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)60733-3
OpenAlex: W2009832071
Cited by: 2,561
References: 61
Citations by year: 2026: 134 · 2025: 135 · 2024: 161 · 2023: 146 · 2022: 182 · 2021: 215 · 2020: 223 · 2019: 221 · 2018: 217 · 2017: 228 · 2016: 255 · 2015: 243 · 2014: 160 · 2013: 36
FWCI: 164.63
Type: journal article
Language: en
Open access: closed
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0611-10150)
H. Lundbeck A/S
Medical Research Council
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, drug efficacy comparison, tolerability, Bayesian framework, weight gain, extrapyramidal symptoms, QTc prolongation, sedation, clozapine, amisulpride, olanzapine, risperidone, paliperidone, zotepine
MeSH terms: Adult, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks